About The Study: This nonrandomized controlled trial of 108 patients with advanced Parkinson disease found that at 5-year follow-up quality of life remained stable in the deep brain stimulation of the subthalamic nucleus (STN-DBS) group and worsened in the standard-of-care medication group, mainly driven by the favorable effect of STN-DBS on mobility. These findings may provide helpful information when counseling patients on the efficacy of STN-DBS for Parkinson disease and monitoring patients postoperatively in long-term follow-up.
Authors: Stefanie T. Jost, Ph.D., and Haidar S. Dafsari, M.D., of the University of Cologne, Germany, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.52177)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.52177?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=011824
Journal
JAMA Network Open